1. Home
  2. HALO vs GGAL Comparison

HALO vs GGAL Comparison

Compare HALO & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • GGAL
  • Stock Information
  • Founded
  • HALO 1998
  • GGAL 1905
  • Country
  • HALO United States
  • GGAL Argentina
  • Employees
  • HALO N/A
  • GGAL N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • GGAL Commercial Banks
  • Sector
  • HALO Health Care
  • GGAL Finance
  • Exchange
  • HALO Nasdaq
  • GGAL Nasdaq
  • Market Cap
  • HALO 7.4B
  • GGAL 6.9B
  • IPO Year
  • HALO N/A
  • GGAL N/A
  • Fundamental
  • Price
  • HALO $66.71
  • GGAL $61.31
  • Analyst Decision
  • HALO Buy
  • GGAL Strong Buy
  • Analyst Count
  • HALO 9
  • GGAL 4
  • Target Price
  • HALO $63.78
  • GGAL $59.00
  • AVG Volume (30 Days)
  • HALO 2.0M
  • GGAL 1.4M
  • Earning Date
  • HALO 05-06-2025
  • GGAL 01-01-0001
  • Dividend Yield
  • HALO N/A
  • GGAL 4.04%
  • EPS Growth
  • HALO 55.40
  • GGAL 120.03
  • EPS
  • HALO 3.76
  • GGAL 1.06
  • Revenue
  • HALO $1,084,306,000.00
  • GGAL $6,697,505,438.00
  • Revenue This Year
  • HALO $20.06
  • GGAL $11.73
  • Revenue Next Year
  • HALO $24.20
  • GGAL N/A
  • P/E Ratio
  • HALO $17.52
  • GGAL $6.25
  • Revenue Growth
  • HALO 25.64
  • GGAL N/A
  • 52 Week Low
  • HALO $41.28
  • GGAL $23.53
  • 52 Week High
  • HALO $70.51
  • GGAL $74.00
  • Technical
  • Relative Strength Index (RSI)
  • HALO 58.91
  • GGAL 50.60
  • Support Level
  • HALO $65.68
  • GGAL $57.11
  • Resistance Level
  • HALO $69.94
  • GGAL $66.24
  • Average True Range (ATR)
  • HALO 2.58
  • GGAL 2.48
  • MACD
  • HALO 0.80
  • GGAL -0.38
  • Stochastic Oscillator
  • HALO 63.69
  • GGAL 24.80

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

Share on Social Networks: